ClinicalTrials.gg
CompletedNCT01032733WL+EUpdated Jun 14, 2012Results posted

Biological Effects of Weight Loss In Older, Obese Women

A Phase 2 interventional study of Lifestyle Counseling and Educational Control in Obesity and Sarcopenia, sponsored by University of Florida. Completed at 1 site in United States. Open to female participants aged 55 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-14.

Sponsored by University of Florida · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
55 Years to 79 Years
Sex
Female
01

Study summary

Obesity and sedentary lifestyle are associated with physical impairments and biological changes in older adults. Weight loss combined with exercise may reduce inflammation and may improve physical functioning in older adults who are overweight or obese and sedentary. However, the mechanisms by which weight change and exercise influence physical functioning and sarcopenia remain largely understudied. ions). In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week throughout the entire study. During each exercise session, participants engaged in both aerobic activities (i.e., walking) and lower body resistance training of moderate intensity. The participants in the educational control group attended monthly health education lectures on topics relevant to older adults. It was hypothesized that participants assigned to the WL+E intervention would 1) lose a larger amount of weight, 2) improve their physical function levels, and 3) reduce levels of oxidative stress and inflammation to a greater degree than participants assigned to the Educational Control group. Outcomes are: 1) body weight, 2) walking speed (assessed by 400 meter walk test), 3) the Short Physical Performance Battery [SPPB], and 4) knee extension isokinetic strength. The objectives of this pilot study are fourfold: 1) to demonstrate the feasibility, acceptability, and efficacy of the proposed WL+E intervention in a sample of 40 sedentary, obese older adults with impaired physical functioning; 2) to examine the biological effects of the intervention on inflammatory processes, oxidative stress, apoptosis, sarcopenia, muscle and body composition, muscle strength, and functional performance; 3) to determine whether the expected beneficial effects of the WL+E intervention on physical functioning are mediated by changes in inflammation, apoptosis, and sarcopenia; and 4) to determine the effect size of the WL+E intervention on key outcomes and provide the basis for sample size calculations in the planning of a larger RCT.

Read the detailed description

SPECIFIC AIMS A.1. Overview Obesity is associated with a higher level of inflammation and oxidative stress, which in turn are important mediators of sarcopenia, declines in physical functioning, and physical limitations in older adults. Several observational studies and randomized controlled trials (RCTs) suggest that behavioral interventions targeting weight loss through caloric restriction plus exercise (CR +EX) may reduce inflammation and may improve function in obese older adults.3 The mechanisms by which CR +EX may influence physical functioning and sarcopenia (the involuntary loss of skeletal muscle with age) remain largely understudied. It is proposed that CR +EX may avert sarcopenia by reducing inflammation, oxidative damage, and consequent apoptosis of skeletal muscle myocytes.

A.2. Objective of the Pilot Study

The proposed pilot study will lay the groundwork for a RCT of the effects of CR +EX on inflammation, oxidative stress, apoptosis, body composition, intramuscular fat, sarcopenia, muscle strength, and physical functioning in obese older adults. The specific objectives of the proposed study are as follows:

  1. Demonstrate the feasibility, acceptability, and efficacy of the proposed intervention, including:

    1. Ability to recruit 40 sedentary, older obese adults with mild to moderate functional disability;
    2. High rate of attendance at treatment sessions (Mean > 75%); and
    3. Good response to treatment (Mean body weight loss > 7%).
  2. Evaluate the biological effects of the CR +EX intervention, including changes in:

    1. Inflammation (i.e., tumor necrosis factor-α [TNF- α], interleukin-6 [IL-6], myeloperoxidase [MPO]);
    2. Oxidative stress (RNA and DNA oxidative damage in leucocytes)
    3. Apoptosis (as assessed by caspases and nuclear DNA fragmentation);
    4. Body composition (as assessed by dual x-ray absorptiometry [DXA)] and
    5. Sarcopenia and muscle composition (i.e., fat free muscle and intramuscular fat, as assessed by Magnetic Resonance Imaging [MRI] and Magnetic Resonance Spectroscopy [MRS]).
  3. Examine functional changes associated with weight loss including:

    1. Upper and lower extremity muscle strength (as measured by grip strength and isometric and isokinetic ankle and knee strength);
    2. Response to the Short Physical Performance Battery; and
    3. Self-reported disability.
  4. Test whether the expected beneficial effects of the CR +EX intervention on physical functioning are mediated by changes in inflammation, oxidative stress, apoptosis, and sarcopenia;
  5. Determine the effect size of the CR +EX intervention on the key outcomes so as to provide the basis for sample size calculations for the planning of the larger RCT.

A.3. Research Hypotheses for the Future RCT

The synergistic effects of CR +EX may be effective in reversing the effects of inflammation, oxidative distress, apoptosis, and sarcopenia on both muscle strength and physical functioning in older adults. Thus, the primary goal of this pilot study is to provide support for a future RCT to test the hypothesis that a lifestyle intervention targeting a 7% loss in body weight through CR + EX will produce greater reductions in these outcomes, as compared to a (no weight loss) control condition. The future RCT would be designed to test the following primary and secondary hypotheses:

Primary hypotheses. As compared with a control condition, the CR +EX Intervention will:

  1. Decrease inflammation (as measured by TNF-α, IL-6, and MPO);
  2. Decrease oxidative stress (as measured by DNA and RNA damage in isolated leucocytes);
  3. Decrease the rate of apoptosis (as measured by caspases and DNA laddering);
  4. Produce favorable changes in body composition (i.e., a decrease in total fat mass and an increase in appendicular lean mass, as assessed by DXA); and
  5. Produce favorable changes in muscle composition (i.e., a decrease in intramuscular fat and an increase in fat-free muscle as assessed by MRI/MRS).
  6. Increase muscle strength and performance (as assessed through validated strength measures)
02

Conditions studied

  • Obesity
  • Sarcopenia

Keywords

  • Weight Loss
  • Physical Function
  • Oxidative Stress
  • Inflammation
03

In context

Obesity

6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.

This study's enrollment of 34 is below the median of 77 across 5,084 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Florida is the lead sponsor of 1,285 studies on the registry; 199 are open to participants now.

Of its 177 completed or terminated interventional studies of FDA-regulated products, 141 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 79 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • African American or Caucasian Female
  • Age between 55 - 79 years
  • BMI > 28 kg/m2
  • sedentary lifestyle (defined as \< 20 min/week of aerobic exercise)
  • mild to moderate physical impairments (score on the Short Physical
  • Performance Battery between 4 - 10).

Exclusion criteria

Exclusion Criteria:

  • Weight >300 lbs.
  • Weight loss > 10 lbs. within the past 6 months
  • History of surgery for weight loss
  • Hospitalization with the past 6 months
  • Significant underlying disease likely to limit lifespan and/or increase risk of interventions (cancer or any condition with a life expectancy \< 5 years with the exception of non-melanoma skin cancer; serious infectious diseases; myocardia infarction, cerebrovascular accident, or unstable angina within the past 6 months; NYHA Class 3 or 4 congestive heart failure; aortic stenosis; chronic hepatitis; cirrhosis; kidney disease; solid organ transplantation; chronic gastrointestinal disorders; fibromyalgia; chronic fatigue syndrome; major psychiatric disorder).
  • Metabolic exclusions (resting blood pressure > 160/90 mmHg, fasting blood glucose > 160 mg/dl, fasting triglycerides > 400 mg/dl; patients on medication for hypertension, diabetes, or hyperlipidemia will not be excluded unless their values suggest "poor control").
  • Medication exclusions (Antipsychotic agents; monoamine oxidase inhibitors; systemic corticosteroids; antibiotics for HIV or TB; chemotherapeutic drugs; or current use of prescription weight-loss drugs).
  • Physical limitations likely to prevent exercise participation (use of walker; breathing problems that limit physical activity).
  • Conditions or behaviors likely to affect the conduct of the trial (e.g., unwilling or unable to give informed consent; unwilling to accept random assignment; likely to move out of area within next 2 years; unable to attend weekly meetings; unwilling to complete paperwork; participation in another randomized research project; unwilling or unable to comply with study requirements or schedule)
  • Contraindications to MRI (MR-incompatible implants or severe claustrophobia).
  • Contraindications to muscle biopsy (i.e., lidocaine allergy)
  • Presence of any other medical condition, which in the opinion of the research staff, would be incompatible with participation in the weight loss plus exercise program.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Lifestyle Counseling

    In the experimental condition, participants attended a group-based weight management session plus three supervised exercise sessions each week.

    Behavioral: Lifestyle Counseling

  • Placebo comparator
    Educational Control

    Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss.

    Other: Educational Control

Interventions

  • BehavioralLifestyle Counseling

    In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.

    Also known as: Weight Loss plus Exercise Intervention

  • OtherEducational Control

    Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).

    Also known as: Health Educational Group

06

What researchers measure

Primary outcomes

  1. Performance on the 400 Meter Walk

    Walking speed was assessed at baseline and 24-week assessment by the 400 Meter Walk Test, during which participants were asked to complete a standard walking course at their usual pace. Participants were permitted to stop during the walk but were not allowed to sit or receive help from others and were required to complete the course in 15 minutes.

    Time frame: 24 weeks

Secondary outcomes

  1. Body Weight

    Body weight was measured under fasting conditions following voiding in the morning at baseline and at the 24-week post-treatment assessment.

    Time frame: 24 weeks

  2. Short Physical Performance Battery

    Scores on the Short Physical Performance Battery (SPPB) were obtained at baseline and at the 24-week post-treatment assessment visit. The SPPB consists of a 4 meter walk, repeated chair stands, and three hierarchical standing balance tests. The time to complete each of the three performance measures was assigned a categorical score based on normative data, ranging from 0 to 4. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding walking speed, chair stands, and balance scores.

    Time frame: 24 weeks

  3. Knee Extension Maximum Isokinetic Strength (Weight Lifted in Kilograms).

    Maximal knee extension strength using each participant's strongest leg was measured using a Biodex. The participants were asked to develop their maximal isokinetic knee extension strength. Three trials of 5 repetitions were performed and the peak torque value was used for statistical analyses.

    Time frame: 24 weeks

  4. Mitochondrial Function (Cox IV Subunit)

    Western blot analysis was performed to determine complex content. The amount of Cox IV subunit was determined for each Reporting Group via Western Blot analysis at baseline and week 24.

    Time frame: 24 weeks

07

Results

Posted Jun 14, 2012
Limitations and caveats
Limitations include the following: (1) the sample size was relatively small,(2)the study was not adequately powered to detect differences between African American and Caucasian women in response to the intervention, (3) inclusion of only women.

Participant flow

Participants were recruited between September 2006 - December 2008 through a variety of methods including media articles, direct mailings, newspaper announcements, and presentations to community groups.

Participant flow — Overall Study
MilestoneLifestyle CounselingEducational Control
Started1717
Completed1616
Not completed11

Outcome measures

PrimaryPerformance on the 400 Meter Walk

Walking speed was assessed at baseline and 24-week assessment by the 400 Meter Walk Test, during which participants were asked to complete a standard walking course at their usual pace. Participants were permitted to stop during the walk but were not allowed to sit or receive help from others and were required to complete the course in 15 minutes.

Time frame:
24 weeks
Reported as:
Mean · meters per second
Performance on the 400 Meter Walk
meters per secondLifestyle CounselingEducational Control
Performance on the 400 Meter Walk0.16 ± 0.030.02 ± 0.03
Statistical analysis
  • Lifestyle Counseling vs Educational Control · ANCOVA · p = <0.05 · Median difference (net): 0.06
SecondaryBody Weight

Body weight was measured under fasting conditions following voiding in the morning at baseline and at the 24-week post-treatment assessment.

Time frame:
24 weeks
Reported as:
Mean · kilograms
Body Weight
kilogramsLifestyle CounselingEducational Control
Body Weight-5.95 ± 4.1-0.23 ± 4.08
Statistical analysis
  • Lifestyle Counseling vs Educational Control · ANCOVA · p = <0.05 · Mean difference (net): 5
SecondaryShort Physical Performance Battery

Scores on the Short Physical Performance Battery (SPPB) were obtained at baseline and at the 24-week post-treatment assessment visit. The SPPB consists of a 4 meter walk, repeated chair stands, and three hierarchical standing balance tests. The time to complete each of the three performance measures was assigned a categorical score based on normative data, ranging from 0 to 4. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding walking speed, chair stands, and balance scores.

Time frame:
24 weeks
Reported as:
Mean · score on the SPPB
Short Physical Performance Battery
score on the SPPBLifestyle CounselingEducational Control
Short Physical Performance Battery1.82 ± 1.240.8 ± 1.20
Statistical analysis
  • Lifestyle Counseling vs Educational Control · Wilcoxon (Mann-Whitney) · p = <0.05 · Mean difference (net): 2
SecondaryKnee Extension Maximum Isokinetic Strength (Weight Lifted in Kilograms).

Maximal knee extension strength using each participant's strongest leg was measured using a Biodex. The participants were asked to develop their maximal isokinetic knee extension strength. Three trials of 5 repetitions were performed and the peak torque value was used for statistical analyses.

Time frame:
24 weeks
Reported as:
Mean · kilograms
Knee Extension Maximum Isokinetic Strength (Weight Lifted in Kilograms).
kilogramsLifestyle CounselingEducational Control
Knee Extension Maximum Isokinetic Strength (Weight Lifted in Kilograms).4.33 ± 14.353.95 ± 14.43
Statistical analysis
  • Lifestyle Counseling vs Educational Control · ANCOVA · p = <0.05 · Mean difference (net): 5
SecondaryMitochondrial Function (Cox IV Subunit)

Western blot analysis was performed to determine complex content. The amount of Cox IV subunit was determined for each Reporting Group via Western Blot analysis at baseline and week 24.

Time frame:
24 weeks
Reported as:
Mean · fold change (ug/ml)
Mitochondrial Function (Cox IV Subunit)
fold change (ug/ml)Lifestyle CounselingEducational Control
Mitochondrial Function (Cox IV Subunit)1.65 ± 0.591.21 ± 0.31
Statistical analysis
  • Lifestyle Counseling vs Educational Control · Wilcoxon (Mann-Whitney) · p = <0.05 · Mean difference (net): 1

Adverse events

Collected over Adverse events were assessed between baseline and six months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lifestyle Counseling—0/17 (0%)7/17 (41.2%)
Educational Control—0/17 (0%)5/17 (29.4%)
Most frequent other events
Most frequent other events
EventLifestyle CounselingEducational Control
MusculoskeletalMusculoskeletal and connective tissue disorders7/175/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lifestyle CounselingEducational ControlTotal
<=18 years000
Between 18 and 65 years121123
>=65 years5611
Age Continuous
Age Continuous(years)Lifestyle CounselingEducational ControlTotal
Mean63.7 ± 4.563.7 ± 6.763.7 ± 5.59
Sex: Female, Male
Sex: Female, Male(Participants)Lifestyle CounselingEducational ControlTotal
Female171734
Male000
Region of Enrollment
Region of Enrollment(participants)Lifestyle CounselingEducational ControlTotal
United States171734
08

Study locations

1 site
  • University of Florida
    Gainesville, Florida 32611, United States
09

References and documents

Publications

  • Anton SD, Manini TM, Milsom VA, Dubyak P, Cesari M, Cheng J, Daniels MJ, Marsiske M, Pahor M, Leeuwenburgh C, Perri MG. Effects of a weight loss plus exercise program on physical function in overweight, older women: a randomized controlled trial. Clin Interv Aging. 2011;6:141-9. doi: 10.2147/CIA.S17001. Epub 2011 Jun 15. PubMed 21753869 ↗
  • Wohlgemuth SE, Lees HA, Marzetti E, Manini TM, Aranda JM, Daniels MJ, Pahor M, Perri MG, Leeuwenburgh C, Anton SD. An exploratory analysis of the effects of a weight loss plus exercise program on cellular quality control mechanisms in older overweight women. Rejuvenation Res. 2011 Jun;14(3):315-24. doi: 10.1089/rej.2010.1132. Epub 2011 Jun 1. PubMed 21631380 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01032733
Responsible party
Sponsor
First posted
Dec 15, 2009
Start date
Sep 2006
Primary completion
Aug 2009
Completion
Oct 2009
Results posted
Jun 14, 2012
Last update
Jun 14, 2012

Study contacts

Stephen D Anton, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion